Ridgeback Biotherapeutics LP
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ridgeback Biotherapeutics LP
The company is developing a next-generation antibody for prevention of COVID-19 that targets highly conserved regions of the SARS-CoV-2 virus and thus may be able to overcome resistance.
AbbVie’s migraine prophylactic and GSK’s treatment for anemia associated with chronic kidney disease were both recommended for pan-EU marketing approval by the European Medicines Agency this week.
MSD/Ridgeback Biotherapeutics’ COVID-19 treatment Lagevrio is among the products that are up for an opinion this week from the European Medicines Agency on whether they should be recommended for use across the EU.
Having played a pivotal role in changing pharma strategy at Bayer, Marianne De Backer tells Scrip about her goal to turn Vir into an infectious disease powerhouse as the firm prepares for critical Phase II data readouts in hepatitis B and D, as well as flu.
- In Vitro Diagnostics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.